New and experimental approaches to treatment of diabetic foot ulcers: A comprehensive review of emerging treatment strategies

Diabetic Medicine

Volumn 21, Issue 11, 2004, Pages 1161-1173

  Eldor, R ^a   Raz, I ^a   Yehuda, A Ben ^a   Boulton, A J M ^b,c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Diabetic foot; Diabetic neuropathy; Foot ulceration; Offloading; Therapy

Indexed keywords

ALGINIC ACID; ANTIBIOTIC AGENT; BECAPLERMIN; CARBOXYMETHYLCELLULOSE; COLLAGEN TYPE 1; CT 102; EPIDERMAL GROWTH FACTOR; ESAVEN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HEPARIN; HYALURONIC ACID; ILOPROST; KETANSERIN; LOW MOLECULAR WEIGHT HEPARIN; PHENYTOIN; PLATELET DERIVED GROWTH FACTOR; POLYMER; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

AMPUTATION; ANTIBIOTIC THERAPY; ARTIFICIAL SKIN; BIOMECHANICS; COST EFFECTIVENESS ANALYSIS; DEBRIDEMENT; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC FOOT; DIABETIC NEUROPATHY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FOOT INJURY; FOOT ULCER; HUMAN; HYDROGEL; HYPERBARIC OXYGEN; MAGGOT DEBRIDEMENT THERAPY; PERIPHERAL VASCULAR DISEASE; REVIEW; RISK FACTOR; SKIN GRAFT; SUB ATMOSPHERIC PRESSURE DRESSING; SUPERNATANT; SURGICAL TECHNIQUE; TREATMENT FAILURE; WOUND CLOSURE; WOUND DRESSING;

BANDAGES; DEBRIDEMENT; DIABETIC FOOT; EVIDENCE-BASED MEDICINE; GROWTH SUBSTANCES; HUMANS; RANDOMIZED CONTROLLED TRIALS; WOUND HEALING;

EID: 8144224013     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01358.x     Document Type: Review

References (101)

1. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999; 22: 382-387.
2. Powers AC. Diabetes Mellitus. In Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL eds. Harrison's Principles of Internal Medicine, 15th edn. New York: McGraw-Hill, 2001: 2125-2126.
3. McCulloch DK. Evaluation of the Diabetic Foot. In Rose BD ed. Wellesley, MA: UpToDate, 2002. http://www.uptodate.com
4. Reiber GE, Vileikyte L, Boyko EJ, del Aguila M, Smith DG, Lavery LA et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 1999; 22: 157-162.
5. Smith RG. Validation of Wagner's classification: a literature review. Ostomy Wound Manage 2003; 49: 54-62.
6. Calhoun JH, Cantrell J, Cobos J, Lacy J, Valdez RR, Hokanson J et al. Treatment of diabetic foot infections: Wagner classification, therapy, and outcome. Foot Ankle 1988; 9: 101-106.
7. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischaemia to risk of amputation. Diabetes Care 1998; 21: 855-859.
8. Watkins PJ. The diabetic foot. Br Med J 2003; 326: 977-979.
9. Blume PA, Paragas LK, Sumpio BE, Attinger CE. Single-stage surgical treatment of noninfected diabetic foot ulcers. Plast Reconstr Surg 2002; 109: 601-609.
10. Piaggesi A, Schipani E, Campi F, Romanelli M, Baccetti F, Arvia C et al. Conservative surgical approach versus non-surgical management for diabetic neuropathic foot ulcers: a randomized trial. Diabet Med 1998; 15: 412-417.
11. Lipsky BA, Pecoraro RE, Larson SA, Hanley ME, Ahroni JH. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch Intern Med 1990; 150: 790-797.
12. Dang CN, Prasad YD, Boulton AJ, Jude EB. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med 2003; 20: 159-161.
13. Tentolouris N, Jude EB, Smirnof I, Knowles EA, Boulton AJ. Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet Med 1999; 16: 767-771.
14. Chantelau E, Tanudjaja T, Altenhofer F, Ersanli Z, Lacigova S, Metzger C. Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes: a controlled trial. Diabet Med 1996; 13: 156-159.
15. Wagner A, Reike H, Angelkort B. Highly resistant pathogens in patients with diabetic foot syndrome with special reference to methicillin-resistant Staphylococcus aureus infections. Dtsch Med Wochenschr 2001; 126: 1353-1356.
16. Roghmann MC, Siddiqui A, Plaisance K, Standiford H. MRSA colonization and the risk of MRSA bacteraemia in hospitalized patients with chronic ulcers. J Hosp Infect 2001; 47: 98-103.
17. Rosenblum BI, Pomposelli FB Jr, Giurini JM, Gibbons GW, Freeman DV, Chrzan JS et al. Maximizing foot salvage by a combined approach to foot ischaemia and neuropathic ulceration in patients with diabetes: a 5-year experience. Diabetes Care 1994; 17: 983-987.
18. Mason J, O'Keeffe C, Hutchinson A, McIntosh A, Young R, Booth A. A systematic review of foot ulcer in patients with Type 2 diabetes mellitus. II. treatment. Diabet Med 1999; 16: 889-909.
19. Armstrong DG, Nguyen HC, Lavery LA, van Schie CH, Boulton AJ, Harkless LBI. Off-Loading the diabetic foot wound: a randomized clinical trial. Diabetes Care 2001; 24: 1019-1022.
20. Armstrong DG, Stacpoole-Shea S. TCC and removable cast walkers. Mitigation of plantar heel pressure. J Am Podiatr Med Assoc 1999; 89: 50-53.
21. Mueller MJ, Diamond JE, Sinacore DR, Delitto A, Blair VP, 3rd Drury DA et al. Total contact casting in treatment of diabetic plantar ulcers. Controlled clinical trial. Diabetes Care 1989; 12: 384-388.
22. Ha Van G, Siney H, Hartmann-Heurtier A, Jacqueminet S, Greau F, Grimaldi A. Nonremovable, windowed, fiberglass cast boot in the treatment of diabetic plantar ulcers: efficacy, safety, and compliance. Diabetes Care 2003; 26: 2848-2852.
23. Spencer S. Pressure relieving interventions for preventing and treating diabetic foot ulcers (Cochrane Review). In: The Cochrane Library. Issue 3. Chichester: John Wiley & Sons Ltd, 2002.
24. Knowles EA, Armstrong DG, Hayat SA, Khawaja KI, Malik RA, Boulton AJ. Offloading diabetic foot wounds using the scotchcast boot: a retrospective study. Ostomy Wound Manage 2002; 48: 50-53.
25. Armstrong DG, Short B, Espensen EH, Abu-Rumman PL, Nixon BP, Boulton AJ. Technique for fabrication of an 'instant total-contact cast' for treatment of neuropathic diabetic foot ulcers. J Am Podiatr Med Assoc 2002; 92: 405-408.
26. Boulton AJM, Armstrong DG. Trials in neuropathic diabetic foot ulcers: time for a paradigm shift? Diabetes Care 2003; 26: 2689-2690.
27. Blackman JD, Senseng D, Quinn L, Mazzone T. Clinical evaluation of a semipermeable polymeric membrane dressing for the treatment of chronic diabetic foot ulcers. Diabetes Care 1994; 17: 322-325.
28. Cullen B, Smith R, McCulloch E, Silcock D, Morrison L. Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair Regen 2002; 10: 16-25.
29. Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg 2002; 137: 822-827.
30. Thomas A, Harding KG, Moore K. Alginates from wound dressings activate human macrophages to secrete tumor necrosis factor-alpha. Biomaterials 2000; 21: 1797-1802.
31. Donaghue VM, Chrzan JS, Rosenblum BI, Giurini JM, Habershaw GM, Veves A. Evaluation of a collagen-alginate wound dressing in the management of diabetic foot ulcers. Adv Wound Care 1998; 11: 114-119.
32. Lalau JD, Bresson R, Charpentier P, Coliche V, Erlher S, Ha Van G et al. Efficacy and tolerance of calcium alginate versus vaseline gauze dressings in the treatment of diabetic foot lesions. Diabetes Metab 2002; 28: 223-229.
33. Williams C. An investigation of the benefits of Aquacel Hydrofibre wound dressing. Br J Nurs 1999; 8: 676-677.
34. Piaggesi A, Baccetti F, Rizzo L, Romanelli M, Navalesi R, Benzi L. Sodium carboxyl-methyl-cellulose dressings in the management of deep ulcerations of diabetic foot. Diabet Med 2001; 18: 320-324.
35. Brunner U, Eberlein T. Experiences with hydrofibres in the moist treatment of chronic wounds, in particular of diabetic foot. Vasa 2000; 29: 253-257.
36. Vazquez JR, Short B, Findlow AH, Nixon BP, Boulton AJ, Armstrong DG. Outcomes of hyaluronan therapy in diabetic foot wounds. Diabetes Res Clin Pract 2003; 59: 123-127.
37. Karvinen S, Pasonen-Seppanen S, Hyttinen JM, Pienimaki JP, Torronen K, Jokela TA et al. Keratinocyte Growth Factor Stimulates Migration and Hyaluronan Synthesis in the Epidermis by Activation of Keratinocyte Hyaluronan Synthases 2 and 3. J Biol Chem 2003; 278: 49495-49504.
38. Armstrong DG, Lavery LA, Abu-Rumman P, Espensen EH, Vazquez JR, Nixon BP et al. Outcomes of subatmospheric pressure dressing therapy on wounds of the diabetic foot. Ostomy Wound Manage 2002; 48: 64-68.
39. Argenta LC, Morykwas MJ. Vacuum-assisted closure: a new method for wound control and treatment: clinical experience. Ann Plast Surg 1997; 38: 563-576.
40. Evans D, Land L. Topical negative pressure for treating chronic wounds (Cochrane Review). In: The Cochrane Library. Issue 4. Chichester: John Wiley & Sons Ltd, 2003.
41. Eginton MT, Brown KR, Seabrook GR, Towne JB, Cambria RA. A Prospective Randomized Evaluation of Negative-pressure Wound Dressings for Diabetic Foot Wounds. Ann Vasc Surg 2003; 17: 645-649.
42. Bloomgarden ZT. American Diabetes Association 60th Scientific Sessions, 2000 The Diabetic Foot. Diabetes Care 2001; 24: 946-951.
43. Gentzkow GD, Iwasaki SD, Hershon KS, Mengel M, Prendergast JJ, Ricotta JJ et al. Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996; 19: 350-354.
44. Hanft JR, Surprenant MS. Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis. J Foot Ankle Surg 2002; 41: 291-299.
45. Marston WA, Hanft J, Norwood P, Pollak R, Dermagraft Diabetic Foot Ulcer Study Group. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 2003; 26: 1701-1705.
46. Veves A, Falanga V, Armstrong DG, Sabolinski ML and the Apligraf Diabetic Foot Ulcer Study. Graftskin, a Human Skin Equivalent, Is Effective in the Management of Noninfected Neuropathic Diabetic Foot Ulcers. Diabetes Care 2001; 24: 290-295.
47. Sams HH, Chen J, King LE. Graftskin treatment of difficult to heal diabetic foot ulcers: one center's experience. Dermatol Surg 2002; 28: 698-703.
48. Moulin V, Lawny F, Barritault D, Caruelle JP. Platelet releasate treatment improves skin healing in diabetic rats through endogenous growth factor secretion. Cell Mol Biol 1998; 44: 961-971.
49. Koveker GB. Growth factors in clinical practice. Int J Clin Pract 2000; 54: 590-593.
50. Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2001; 24: 483-488.
51. Steed DL, Goslen JB, Holloway GA, Malone JM, Bunt TJ, Webster MW. Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo. Diabetes Care 1992; 15: 1598-1604.
52. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998; 21: 822-827.
53. Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 1999; 7: 335-346.
54. FDA (1997) Platelet-derived growth factor-BB (Becaplermin). [WWW document] URL http://www.fda.gov/cder/biologics/products/becaomj121697.htm
55. Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatol Surg 2001; 27: 347-351.
56. Ghatnekar O, Persson U, Willis M, Odegaard K. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four. European Countries Pharmacoeconomics 2001; 19: 767-778.
57. Sibbald RG, Torrance G, Hux M, Attard C, Milkovich N. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers. Ostomy Wound Manage 2003; 49: 76-84.
58. Tsang MW, Wong WK, Hung CS, Lai KM, Tang W, Cheung EY et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care 2003; 26: 1856-1861.
59. Yonem A, Cakir B, Guler S, Azal OO, Corakci A. Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes Metab 2001; 3: 332-337.
60. Kastenbauer T, Hornlein B, Sokol G, Irsigler K. Evaluation of granulocyte-colony stimulating factor (Filgrastim) in infected diabetic foot ulcers. Diabetologia 2003; 46: 27-30.
61. Lazareth I. Local care and medical treatment for ischemic diabetic ulcers. J Mal Vasc 2002; 27: 157-163.
62. de Lalla F, Pellizzer G, Strazzabosco M, Martini Z, Du Jardin G, Lora L et al. Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrob Agents Chemother 2001; 45: 1094-1098.
63. Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J, Edmonds ME. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet 1997; 350: 855-859.
64. Jude EB, Blakytny R, Bulmer J, Boulton AJ, Ferguson MW. Transforming growth factor-beta 1, 2, 3 and receptor type I and II in diabetic foot ulcers. Diabet Med 2002; 19: 440-447.
65. Jude EB, Boulton AJ, Ferguson MW, Appleton I. The role of nitric oxide synthase isoforms and arginase in the pathogenesis of diabetic foot ulcers: possible modulatory effects by transforming growth factor beta 1. Diabetologia 1999; 42: 748-757.
66. Limova M. New therapeutic options for chronic wounds. Dermatol Clin 2000; 20: 357-363.
67. Brock FE, Abri O, Baitsch G, Bechara G, Beck K, Corovic D et al. Iloprost in the treatment of ischemic tissue lesions in diabetics. Results of a placebo-controlled multicenter study with a stable prostacyclin derivative. Schweiz Med Wochenschr 1990; 120: 1477-1482.
68. O'Meara S, Cullum N, Majid M, Sheldon T. Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration. Health Technol Assess 2000; 4: 1-237.
69. Talas G, Brown RA, McGrouther DA. Role of phenytoin in wound healing-a wound pharmacology perspective. Biochem Pharmacol 1999; 57: 1085-1094.
70. Muthukumarasamy MG, Sivakumar G, Manoharan G. Topical phenytoin in diabetic foot ulcers. Diabetes Care 1991; 14: 909-911.
71. Pai MR, Sitaraman N, Kotian MS. Topical phenytoin in diabetic ulcers: a double blind controlled trial. Indian J Med Sci 2001; 55: 593-599.
72. Di Mauro C, Ossino AM, Trefiletti M, Polosa P, Beghe F. Lyophilized collagen in the treatment of diabetic ulcers. Drugs Exp Clin Res 1991; 17: 371-373.
73. Martinez-de Jesus FR, Morales-Guzman M, Castaneda M, Perez-Morales A, Garcia-Alonso J, Mendiola-Segura I. Randomized single-blind trial of topical ketanserin for healing acceleration of diabetic foot ulcers. Arch Med Res 1997; 28: 95-99.
74. Apelqvist J, Castenfors J, Larsson J, Stenstrom A, Persson G. Ketanserin in the treatment of diabetic foot ulcer with severe peripheral vascular disease. Int Angiol 1990; 9: 120-124.
75. Belcaro G, Nicolaides AN, Geroulakos G, Cesarone MR, Incandela L, De Sanctis MT. Essaven gel - review of experimental and clinical data. Angiology 2001; 52: S1-4.
76. Cesarone MR, Incandela L, Belcaro G, De Sanctis MT, Ricci A, Griffin M. Two-week topical treatment with Essaven gel in patients with diabetic microangiopathy-a placebo-controlled, randomized study. Angiology 2001; 52: S43-48.
77. Incandela L, Belcaro G, Cesarone MR, De Sanctis MT, Griffin M. Microvascular alterations in diabetic microangiopathy: topical treatment with Essaven gel-a placebo-controlled, randomized study. Angiology 2001; 52: S35-41.
78. Jorneskog G, Brismar K, Fagrell B. Low molecular weight heparin seems to improve local capillary circulation and healing of chronic foot ulcers in diabetic patients. Vasa 1993; 22: 137-142.
79. Boykin JV Jr. The nitric oxide connection: hyperbaric oxygen therapy, becaplermin, and diabetic ulcer management. Adv Skin Wound Care 2000; 13: 169-174.
80. Leslie CA, Sapico FL, Ginunas VJ, Adkins RH. Randomized controlled trial of topical hyperbaric oxygen for treatment of diabetic foot ulcers. Diabetes Care 1988; 11: 111-115.
81. Landau Z, Schattner A. Topical hyperbaric oxygen and low energy laser therapy for chronic diabetic foot ulcers resistant to conventional treatment. Yale J Biol Med 2001; 74: 95-100.
82. Kalani M, Jorneskog G, Naderi N, Lind F, Brismar K. Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers. Long-term follow-up. J Diabetes Complications 2002; 16: 153-158.
83. Faglia E, Favales F, Aldeghi A, Calia P, Quarantiello A, Oriani G et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. Diabetes Care 1996; 19: 1338-1343.
84. Abidia A, Laden G, Kuhan G, Johnson BF, Wilkinson AR, Renwick PM et al. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial. Eur J Vasc Endovasc Surg 2003; 25: 513-518.
85. Kessler L, Bilbault P, Ortega F, Grasso C, Passemard R, Stephan D et al. Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diabetes Care 2003; 26: 2378-2382.
86. Wunderlich RP, Peters EJ, Lavery LA. Systemic hyperbaric oxygen therapy: lower-extremity wound healing and the diabetic foot. Diabetes Care 2000; 23: 1551-1555.
87. Senior C. Treatment of diabetic foot ulcers with hyperbaric oxygen. J Wound Care 2000; 9: 193-197.
88. Gilcreast DM, Stotts NA, Froelicher ES, Baker LL, Moss KM. Effect of electrical stimulation on foot skin perfusion in persons with or at risk for diabetic foot ulcers. Wound Repair Regen 1998; 6: 434-441.
89. Peters EJ, Armstrong DG, Wunderlich RP, Bosma J, Stacpoole-Shea S, Lavery LA. The benefit of electrical stimulation to enhance perfusion in persons with diabetes mellitus. J Foot Ankle Surg 1998; 37: 396-400.
90. Lundeberg TC, Eriksson SV, Malm M. Electrical nerve stimulation improves healing of diabetic ulcers. Ann Plast Surg 1992; 29: 328-331.
91. Baker LL, Chambers R, DeMuth SK, Villar F. Effects of electrical stimulation on wound healing in patients with diabetic ulcers. Diabetes Care 1997; 20: 405-412.
92. Mumcuoglu KY. Clinical applications for maggots in wound care. Am J Clin Dermatol 2001; 2: 219-227.
93. Mumcuoglu KY, Lipo M, Ioffe-Uspensky I, Miller J, Galun R. Maggot therapy for gangrene and osteomyelitis. Harefuah 1997; 132: 382.
94. Stoddard SR, Sherman RA, Mason BE, Pelsang DJ, Sherman RA. Maggot debridement therapy. An alternative treatment for non-healing ulcers. J Am Podiatr Med Assoc 1995; 85: 218-221.
95. Mumcuoglu KY, Ingber A, Gilead L, Stessman J, Friedmann R, Schulman H et al. Maggot therapy for the treatment of diabetic foot ulcers. Diabetes Care 1998; 21: 2030-2031.
96. Knowles A, Findlow A, Jackson N. Management of a diabetic foot ulcer using larval therapy. Nurs Stand 2001; 16: 73-76.
97. Sherman RA. Maggot therapy for treating diabetic foot ulcers unresponsive to conventional therapy. Diabetes Care 2003; 26: 446-451.
98. Smith J. Debridement of diabetic foot ulcers (Cochrane Review). In The Cochrane Library. Issue 4 Chichester: John Wiley & Sons Ltd, 2003.
99. D'Hemecourt PA, Smiell JM, Karim MR. Sodium carboxymethyl cellulose aqueous-based gel vs becaplermin gel in patients with non-healing lower extremity diabetic ulcers. Wounds 1998; 10: 69-75.
100. Jensen JL, Seeley J, Gillin B. Diabetic foot ulcerations: a controlled, randomized comparison of two moist wound healing protocols: Carrasyn Hydrogel wound dressing and wet-to-moist saline gauze. Adv Wound Care 1998; 11: 1-4.
101. Vandeputte J, Gryson L. Diabetic foot infection controlled by immuno-modulating hydrogel containing 65% glycerine. Presentation of a clinical trial. In 6th European Conference on Advances in Wound Management, Amsterdam, October 1996. London: Macmillan Magazines, 1997: 50-53.